Molecular Templates Inc. (MTI) is a biopharmaceutical company with a novel protein platform for the development of new therapeutics against cancer. The company has a lead compound for melanoma that is expected to enter into clinical trials in the next two years and is developing additional compounds against a variety of other cancers.